Avalo Therapeutics (AVTX) Competitors $12.96 -0.04 (-0.31%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVTX vs. SLGL, VINC, GLYC, DRRX, OCX, VNRX, THTX, DTIL, KZR, and CDTXShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Sol-Gel Technologies (SLGL), Vincerx Pharma (VINC), GlycoMimetics (GLYC), DURECT (DRRX), OncoCyte (OCX), VolitionRx (VNRX), Theratechnologies (THTX), Precision BioSciences (DTIL), Kezar Life Sciences (KZR), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Sol-Gel Technologies Vincerx Pharma GlycoMimetics DURECT OncoCyte VolitionRx Theratechnologies Precision BioSciences Kezar Life Sciences Cidara Therapeutics Avalo Therapeutics (NASDAQ:AVTX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the MarketBeat Community favor AVTX or SLGL? Sol-Gel Technologies received 144 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 63.40% of users gave Sol-Gel Technologies an outperform vote while only 29.41% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes529.41% Underperform Votes1270.59% Sol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% Which has stronger valuation and earnings, AVTX or SLGL? Sol-Gel Technologies has lower revenue, but higher earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$1.92M6.96-$31.54MN/AN/ASol-Gel Technologies$1.55M9.17-$27.24M-$0.54-0.94 Do analysts rate AVTX or SLGL? Sol-Gel Technologies has a consensus price target of $5.00, suggesting a potential upside of 880.20%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AVTX or SLGL? In the previous week, Avalo Therapeutics had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for Avalo Therapeutics and 0 mentions for Sol-Gel Technologies. Avalo Therapeutics' average media sentiment score of 1.09 beat Sol-Gel Technologies' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Avalo Therapeutics Positive Sol-Gel Technologies Neutral Do insiders and institutionals have more ownership in AVTX or SLGL? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, AVTX or SLGL? Avalo Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Is AVTX or SLGL more profitable? Avalo Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -227.40%. Sol-Gel Technologies' return on equity of -39.95% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -306.52% 113.09% Sol-Gel Technologies -227.40%-39.95%-33.69% SummarySol-Gel Technologies beats Avalo Therapeutics on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.35M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E RatioN/A9.36112.5515.07Price / Sales6.96386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book1.425.324.645.01Net Income-$31.54M$153.56M$119.13M$225.46M7 Day Performance-10.21%0.12%0.78%0.37%1 Month Performance27.11%15.23%5.65%3.57%1 Year Performance-47.19%41.16%36.90%29.42% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics2.0004 of 5 stars$12.97-0.3%N/A-45.0%$13.35M$1.92M0.0040Gap UpSLGLSol-Gel Technologies2.4605 of 5 stars$0.65-1.5%$5.00+673.9%-60.8%$18.00M$6.56M-1.2050Gap UpVINCVincerx Pharma3.1275 of 5 stars$0.37-2.6%$2.00+436.9%-59.7%$11.05MN/A-0.2860Gap DownGLYCGlycoMimetics4.3859 of 5 stars$0.17flat$10.00+5,845.3%-69.6%$10.84M$10,000.00-0.2950Analyst ForecastOptions VolumeNews CoverageDRRXDURECT2.7703 of 5 stars$1.48+3.5%$21.00+1,318.9%-55.0%$45.94M$8.41M-2.4380Positive NewsOCXOncoCyte2.1533 of 5 stars$3.10+2.0%$4.06+31.0%+29.3%$52.17M$1.50M0.00120Analyst ForecastVNRXVolitionRx1.8302 of 5 stars$0.63-10.0%$2.50+296.8%-18.3%$58.03M$770,000.00-1.5880News CoverageGap UpTHTXTheratechnologiesN/A$1.26+2.4%N/A+37.1%$57.94M$84.32M-12.60140Gap UpDTILPrecision BioSciences4.0207 of 5 stars$8.28-1.1%$39.50+377.1%-24.6%$57.35M$87.64M39.83200Upcoming EarningsKZRKezar Life Sciences4.0418 of 5 stars$0.77-1.3%$4.50+482.5%-5.2%$57.20M$7M-0.5760Stock SplitCDTXCidara Therapeutics4.2839 of 5 stars$12.47-1.0%$29.67+137.9%-18.5%$56.89M$53.87M-0.5090Upcoming EarningsNews Coverage Related Companies and Tools Related Companies Sol-Gel Technologies Competitors Vincerx Pharma Competitors GlycoMimetics Competitors DURECT Competitors OncoCyte Competitors VolitionRx Competitors Theratechnologies Competitors Precision BioSciences Competitors Kezar Life Sciences Competitors Cidara Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
